Episode 33: A Review on exl's 12th Partnering with ACOs and IDNs Summit
Episode Summary
John is taking the helm this week to share his experience presenting at a conference last week, and the lessons he learned from two days of sessions. We will return to our regular format next week. The conference, exl’s 12th Partnering with ACOs and IDNs Summit, included about 100 people, mostly represented by pharma, ACOs and health systems.
Episode Notes
John is taking the helm this week to share his experience presenting at a conference last week, and the lessons he learned from two days of sessions. We will return to our regular format next week. The conference, exl’s 12th Partnering with ACOs and IDNs Summit, included about 100 people, mostly represented by pharma, ACOs and health systems.
- The first part of his presentation covered what we learned from our annual ACO Executive survey, which includes what are their most pressing problems.
- The second part delved into the partnering, or lack thereof, of pharma companies with ACOs.
About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.
CONNECT WITH US:
🌐 Follow Health Care Rounds on LinkedIn
🌐 Follow Darwin Research Group on LinkedIn
📺 Watch Health Care Rounds on YouTube
⚙️ Health Care Rounds is produced by Grippi Media
Recommended Next
Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Subscribe to Our Take
Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.







